Diabetes

January 15, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: Fluoxetine[Trade name: Prozac and Sarafem], an antidepressant,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 16/January/2018, 4.55 am

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour […]
January 12, 2018

Vitamin-based combinatorial therapy for reversing TIIDM: A pharmaceutical mixture encompassing Vitamin-B12  and Omega-3-fatty acids (VB12O3FA)  augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 12/January/2017, 11.22 pm

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
January 11, 2018

Combinatorial therapy for reversing TIIDM: A pharmaceutical mixture encompassing (TMZATX) Trimetazidine (TMZ) and Astaxanthin (ATX) augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 11/January/2017, 10.51 pm

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
January 11, 2018

Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: A therapeutic mix encompassing Aspalathin and Nothofagin, isolated from Rooibos, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 11/January/2018, 10.37 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]